- Diabetes, Obesity and Metabolism
- The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
-
Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
-
Endocrinol Metab. 2022;37(3):455-465. Published online June 21, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1434
-
-
7,059
View
-
163
Download
-
18
Web of Science
-
18
Crossref
-
Abstract
PDF Supplementary Material PubReader ePub
- Background
We aimed to investigate the association of hepatic steatosis with liver fibrosis and to assess the interactive effects of hepatic steatosis and insulin resistance on liver fibrosis in a nationally representative sample of United States adults.
Methods We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2017 to 2018, which for the first time included transient elastography to assess liver stiffness and hepatic steatosis. We evaluated the association between hepatic steatosis (using controlled attenuation parameter [CAP]) and clinically significant liver fibrosis (defined as liver stiffness ≥7.5 kPa) using logistic regression with an interaction term for hepatic steatosis and insulin resistance (defined as homeostatic model assessment of insulin resistance ≥3.0).
Results Among adults undergoing transient elastography (n=2,023), 45.9% had moderate or greater hepatic steatosis and 11.3% had clinically significant liver fibrosis. After adjustment for demographic and metabolic factors, the odds of significant liver fibrosis increased as CAP score rose (odds ratio, 1.35 per standard deviation increment; 95% confidence interval, 1.11 to 1.64). We detected a significant interaction effect between CAP score and insulin resistance on the probability of significant liver fibrosis (P=0.016 for interaction). The probability of significant liver fibrosis increased in the presence of insulin resistance with increasing CAP score, while those without insulin resistance had low probability of significant liver fibrosis, even with high CAP scores.
Conclusion Individuals with hepatic steatosis had higher odds of fibrosis when insulin resistance was present. Our findings emphasize the importance of the metabolic aspects of the disease on fibrosis risk and suggest a need to better identify patients with metabolic associated fatty liver disease.
-
Citations
Citations to this article as recorded by 
- Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song Hepatology International.2025; 19(1): 181. CrossRef - Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen BMC Gastroenterology.2025;[Epub] CrossRef - The Value of TyG‐Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD
Haoxuan Zou, Jiejie Xie, Xiaopu Ma, Yan Xie, Xingshun Qi Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef - Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi Cells.2025; 14(6): 428. CrossRef - Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Hepatic Steatosis in Insulin Resistance and Metabolic Health
Ji Cheol Bae Endocrinology and Metabolism.2025; 40(2): 304. CrossRef - Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome
Tzu-chia Kuo, Yang-bor Lu, Chieh-lun Yang, Bin Wang, Lin-xin Chen, Ching-ping Su BMC Gastroenterology.2024;[Epub] CrossRef - No More NAFLD: The Term Is Now MASLD
Ji Cheol Bae Endocrinology and Metabolism.2024; 39(1): 92. CrossRef - Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis
Mohammad E. Khamseh, Mojtaba Malek, Soodeh Jahangiri, Sohrab Nobarani, Azita Hekmatdoost, Marieh Salavatizadeh, Samira Soltanieh, Haleh Chehrehgosha, Hoda Taheri, Zeinab Montazeri, Fereshteh Attaran, Faramarz Ismail-Beigi, Fariba Alaei-Shahmiri Digestive Diseases and Sciences.2024; 69(4): 1430. CrossRef - The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
Murat Keskin, Sercan Avul, Aylin Beyaz, Nizameddin Koca Heliyon.2024; 10(5): e27291. CrossRef - Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial
Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan Gastro Hep Advances.2024; 3(3): 417. CrossRef - Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
Mehwish Qamar, Abeer Fatima, Ambreen Tauseef, Muhammad I Yousufzai, Ibrahim Liaqat, Qanbar Naqvi Cureus.2024;[Epub] CrossRef - Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won-Young Lee Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef - Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Shahid Habib World Journal of Gastrointestinal Pathophysiology.2024;[Epub] CrossRef - Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae Endocrinology and Metabolism.2023; 38(4): 418. CrossRef - Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi Cell Death & Disease.2023;[Epub] CrossRef - Familial clustering of nonalcoholic fatty liver disease in first‐degree relatives of adults with lean nonalcoholic fatty liver disease
Sorachat Niltwat, Chanin Limwongse, Natthinee Charatcharoenwitthaya, Duangkamon Bunditvorapoom, Wimolrak Bandidniyamanon, Phunchai Charatcharoenwitthaya Liver International.2023; 43(12): 2713. CrossRef - Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
Jun-Hyuk Lee, Yu-Jin Kwon, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Nutrients.2022; 14(15): 3039. CrossRef - DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
Ji Cheol Bae Endocrinology and Metabolism.2022; 37(6): 858. CrossRef
|